Savient Pharmaceuticals Inc. (Nasdaq: SVNT) failed to sell itself despite approval from the Food and Drug Administration last month for its gout treatment Krystexxa sending the stock price plummeting $9.04 to $12.66.
No Sale For Savient
October 25, 2010 at 13:05 PM EDT
